| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Marrow Transplantation | 79 | 2024 | 2709 | 5.250 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 98 | 2024 | 5717 | 5.120 |
Why?
|
| Transplantation Conditioning | 63 | 2023 | 1601 | 3.560 |
Why?
|
| Transplantation Chimera | 28 | 2022 | 594 | 2.510 |
Why?
|
| Graft vs Host Disease | 68 | 2024 | 3049 | 2.280 |
Why?
|
| Cord Blood Stem Cell Transplantation | 18 | 2020 | 305 | 2.280 |
Why?
|
| Hematologic Neoplasms | 32 | 2021 | 1907 | 2.240 |
Why?
|
| Kidney Transplantation | 22 | 2023 | 4262 | 1.290 |
Why?
|
| Transplantation, Homologous | 49 | 2021 | 4833 | 1.210 |
Why?
|
| Histocompatibility Testing | 19 | 2019 | 716 | 1.150 |
Why?
|
| Tissue Donors | 13 | 2024 | 2381 | 1.090 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 10 | 2020 | 225 | 1.080 |
Why?
|
| Kidney Failure, Chronic | 11 | 2019 | 2496 | 1.070 |
Why?
|
| HLA Antigens | 11 | 2019 | 1334 | 1.060 |
Why?
|
| Transplantation Tolerance | 8 | 2023 | 633 | 1.000 |
Why?
|
| Hematologic Diseases | 5 | 2023 | 498 | 0.980 |
Why?
|
| Bone Marrow | 13 | 2024 | 2935 | 0.920 |
Why?
|
| Transplantation, Autologous | 30 | 2017 | 2120 | 0.870 |
Why?
|
| Stem Cell Transplantation | 12 | 2015 | 1596 | 0.870 |
Why?
|
| Cyclophosphamide | 21 | 2023 | 2227 | 0.800 |
Why?
|
| Myeloablative Agonists | 7 | 2018 | 210 | 0.780 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 9 | 2020 | 631 | 0.770 |
Why?
|
| Whole-Body Irradiation | 12 | 2019 | 435 | 0.690 |
Why?
|
| Busulfan | 11 | 2015 | 259 | 0.680 |
Why?
|
| Histocompatibility | 5 | 2012 | 321 | 0.650 |
Why?
|
| Leukemia | 15 | 2018 | 1519 | 0.640 |
Why?
|
| Swine, Miniature | 12 | 2015 | 965 | 0.640 |
Why?
|
| Leukemia, Myeloid, Acute | 13 | 2019 | 3626 | 0.600 |
Why?
|
| Multiple Myeloma | 11 | 2019 | 5196 | 0.580 |
Why?
|
| Bone Marrow Cells | 9 | 2024 | 2414 | 0.570 |
Why?
|
| Fetal Blood | 8 | 2019 | 1361 | 0.570 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 7 | 2018 | 263 | 0.550 |
Why?
|
| Immune Tolerance | 13 | 2019 | 2323 | 0.550 |
Why?
|
| Graft Survival | 20 | 2019 | 3887 | 0.510 |
Why?
|
| Blood Donors | 7 | 2020 | 343 | 0.490 |
Why?
|
| Lymphocyte Transfusion | 6 | 2018 | 232 | 0.490 |
Why?
|
| Lymphoma | 12 | 2022 | 1898 | 0.480 |
Why?
|
| Chimerism | 5 | 2023 | 156 | 0.450 |
Why?
|
| Hematopoietic Stem Cells | 8 | 2020 | 3409 | 0.430 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2014 | 1375 | 0.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2015 | 11878 | 0.430 |
Why?
|
| Haplotypes | 8 | 2012 | 2722 | 0.420 |
Why?
|
| HLA-A2 Antigen | 1 | 2012 | 207 | 0.400 |
Why?
|
| Haploidy | 4 | 2010 | 127 | 0.400 |
Why?
|
| Sarcoma, Myeloid | 1 | 2012 | 52 | 0.390 |
Why?
|
| Humans | 219 | 2024 | 768166 | 0.380 |
Why?
|
| Transplantation Immunology | 7 | 2015 | 537 | 0.370 |
Why?
|
| Middle Aged | 112 | 2024 | 223492 | 0.360 |
Why?
|
| Nausea | 3 | 2000 | 682 | 0.360 |
Why?
|
| Transplants | 2 | 2016 | 208 | 0.360 |
Why?
|
| Adult | 119 | 2024 | 223646 | 0.350 |
Why?
|
| Hepatic Veno-Occlusive Disease | 6 | 2010 | 220 | 0.340 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2005 | 121 | 0.340 |
Why?
|
| Organ Transplantation | 2 | 2015 | 1176 | 0.320 |
Why?
|
| Affect | 5 | 2019 | 1495 | 0.320 |
Why?
|
| Tumor Escape | 1 | 2012 | 372 | 0.320 |
Why?
|
| Disease-Free Survival | 17 | 2019 | 6847 | 0.320 |
Why?
|
| Capillary Leak Syndrome | 3 | 2011 | 34 | 0.310 |
Why?
|
| Myelodysplastic Syndromes | 7 | 2018 | 1399 | 0.310 |
Why?
|
| T-Lymphocytes | 17 | 2018 | 10266 | 0.300 |
Why?
|
| Female | 124 | 2024 | 397192 | 0.290 |
Why?
|
| Male | 118 | 2024 | 364719 | 0.290 |
Why?
|
| Graft vs Tumor Effect | 2 | 2008 | 68 | 0.290 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2008 | 79 | 0.290 |
Why?
|
| Ondansetron | 2 | 2000 | 95 | 0.280 |
Why?
|
| Combined Modality Therapy | 22 | 2021 | 8542 | 0.270 |
Why?
|
| Lymphocytes | 5 | 2018 | 2614 | 0.270 |
Why?
|
| Anemia, Aplastic | 4 | 1996 | 231 | 0.270 |
Why?
|
| Vascular Diseases | 1 | 2015 | 1162 | 0.270 |
Why?
|
| Vidarabine | 6 | 2019 | 337 | 0.260 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 1886 | 0.250 |
Why?
|
| Graft Rejection | 13 | 2015 | 4492 | 0.250 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 812 | 0.250 |
Why?
|
| Quality of Life | 10 | 2020 | 13490 | 0.250 |
Why?
|
| Immunosuppressive Agents | 8 | 2019 | 4206 | 0.250 |
Why?
|
| Antilymphocyte Serum | 6 | 2016 | 492 | 0.240 |
Why?
|
| Parathyroid Hormone | 2 | 2012 | 1804 | 0.240 |
Why?
|
| Paraproteinemias | 3 | 2015 | 252 | 0.240 |
Why?
|
| Melphalan | 6 | 2019 | 421 | 0.240 |
Why?
|
| Aged | 64 | 2024 | 171504 | 0.240 |
Why?
|
| Etoposide | 5 | 2012 | 639 | 0.230 |
Why?
|
| Carboplatin | 5 | 2002 | 797 | 0.230 |
Why?
|
| Primary Myelofibrosis | 3 | 2023 | 209 | 0.230 |
Why?
|
| Gene Deletion | 1 | 2012 | 2675 | 0.230 |
Why?
|
| Isoantibodies | 3 | 2014 | 681 | 0.230 |
Why?
|
| Tissue and Organ Harvesting | 3 | 2024 | 373 | 0.220 |
Why?
|
| Physicians | 1 | 2022 | 4598 | 0.220 |
Why?
|
| Interleukin-2 | 7 | 2003 | 1895 | 0.220 |
Why?
|
| Hodgkin Disease | 3 | 2011 | 1384 | 0.220 |
Why?
|
| Endothelium, Vascular | 2 | 2015 | 4427 | 0.220 |
Why?
|
| Lymphocyte Depletion | 8 | 2016 | 605 | 0.210 |
Why?
|
| Isoantigens | 1 | 2005 | 562 | 0.210 |
Why?
|
| Niacinamide | 2 | 2016 | 418 | 0.210 |
Why?
|
| Vomiting | 2 | 1998 | 655 | 0.210 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2019 | 1560 | 0.200 |
Why?
|
| Syndrome | 5 | 2015 | 3272 | 0.200 |
Why?
|
| Recurrence | 10 | 2020 | 8509 | 0.200 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2008 | 2204 | 0.200 |
Why?
|
| Phenylurea Compounds | 2 | 2016 | 531 | 0.200 |
Why?
|
| Acute Disease | 15 | 2024 | 7243 | 0.200 |
Why?
|
| Quality of Health Care | 1 | 2017 | 4310 | 0.200 |
Why?
|
| Survival Analysis | 16 | 2018 | 10101 | 0.190 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2016 | 494 | 0.190 |
Why?
|
| Swine | 16 | 2016 | 5995 | 0.190 |
Why?
|
| Swine Diseases | 2 | 2012 | 61 | 0.180 |
Why?
|
| Nepal | 1 | 2022 | 301 | 0.180 |
Why?
|
| Remission Induction | 8 | 2016 | 2410 | 0.180 |
Why?
|
| Granisetron | 1 | 2000 | 7 | 0.180 |
Why?
|
| Mycoses | 3 | 2013 | 386 | 0.170 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 299 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2022 | 928 | 0.170 |
Why?
|
| Antiemetics | 2 | 2000 | 188 | 0.170 |
Why?
|
| Pneumocystis | 1 | 1999 | 55 | 0.170 |
Why?
|
| Immunoconjugates | 2 | 2018 | 975 | 0.170 |
Why?
|
| Living Donors | 3 | 2018 | 647 | 0.170 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 1993 | 667 | 0.170 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2020 | 130 | 0.170 |
Why?
|
| Tandem Repeat Sequences | 2 | 2016 | 183 | 0.170 |
Why?
|
| Anxiety | 5 | 2020 | 4672 | 0.170 |
Why?
|
| Naphthoquinones | 1 | 1999 | 60 | 0.170 |
Why?
|
| Treatment Outcome | 34 | 2024 | 65371 | 0.160 |
Why?
|
| Salvage Therapy | 4 | 2009 | 1273 | 0.160 |
Why?
|
| Somatostatin | 1 | 2021 | 458 | 0.160 |
Why?
|
| Pilot Projects | 8 | 2024 | 8741 | 0.160 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 686 | 0.160 |
Why?
|
| Immunologic Memory | 3 | 2015 | 1377 | 0.160 |
Why?
|
| Kidney Diseases | 4 | 2015 | 2100 | 0.150 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2022 | 1512 | 0.150 |
Why?
|
| Arthritis, Gouty | 1 | 1998 | 28 | 0.150 |
Why?
|
| Palliative Care | 3 | 2017 | 3643 | 0.150 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1999 | 242 | 0.150 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2022 | 302 | 0.150 |
Why?
|
| Leukocyte Transfusion | 3 | 2003 | 56 | 0.140 |
Why?
|
| Flow Cytometry | 9 | 2015 | 5902 | 0.140 |
Why?
|
| Thymus Gland | 4 | 2010 | 1266 | 0.140 |
Why?
|
| Nursing Assessment | 2 | 1994 | 107 | 0.140 |
Why?
|
| Retrospective Studies | 31 | 2024 | 81762 | 0.140 |
Why?
|
| Caregivers | 3 | 2020 | 2302 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 8 | 2010 | 9263 | 0.130 |
Why?
|
| Intestinal Diseases | 2 | 2012 | 505 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2010 | 2298 | 0.130 |
Why?
|
| HLA-C Antigens | 1 | 2016 | 146 | 0.130 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2017 | 124 | 0.130 |
Why?
|
| Adolescent | 36 | 2019 | 89169 | 0.130 |
Why?
|
| Bacteremia | 2 | 2020 | 986 | 0.130 |
Why?
|
| Anemia | 3 | 2017 | 1514 | 0.130 |
Why?
|
| Survival Rate | 13 | 2019 | 12840 | 0.130 |
Why?
|
| Staphylococcal Protein A | 2 | 1985 | 39 | 0.130 |
Why?
|
| Arabinonucleosides | 1 | 2015 | 34 | 0.130 |
Why?
|
| Polydeoxyribonucleotides | 2 | 2010 | 136 | 0.130 |
Why?
|
| Cytapheresis | 1 | 2015 | 8 | 0.130 |
Why?
|
| Depression | 6 | 2020 | 8230 | 0.120 |
Why?
|
| Adenine Nucleotides | 1 | 2015 | 110 | 0.120 |
Why?
|
| Breast Neoplasms | 6 | 2012 | 21206 | 0.120 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 116 | 0.120 |
Why?
|
| Blood Specimen Collection | 1 | 2016 | 238 | 0.120 |
Why?
|
| Dyskeratosis Congenita | 1 | 2015 | 70 | 0.120 |
Why?
|
| Animals | 33 | 2023 | 169246 | 0.120 |
Why?
|
| Antineoplastic Agents | 6 | 2016 | 13676 | 0.120 |
Why?
|
| Decidua | 1 | 2015 | 82 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2017 | 4648 | 0.120 |
Why?
|
| Chimera | 2 | 1999 | 454 | 0.120 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2015 | 121 | 0.120 |
Why?
|
| Young Adult | 23 | 2020 | 60066 | 0.120 |
Why?
|
| Incidence | 7 | 2023 | 21538 | 0.120 |
Why?
|
| Dermatitis, Exfoliative | 1 | 2014 | 27 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 2568 | 0.120 |
Why?
|
| Antifungal Agents | 1 | 1999 | 761 | 0.120 |
Why?
|
| Environment, Controlled | 1 | 1994 | 42 | 0.110 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2018 | 364 | 0.110 |
Why?
|
| Polycythemia | 1 | 2015 | 124 | 0.110 |
Why?
|
| Urate Oxidase | 1 | 2014 | 31 | 0.110 |
Why?
|
| Models, Animal | 4 | 2017 | 2120 | 0.110 |
Why?
|
| Fever | 2 | 2014 | 1614 | 0.110 |
Why?
|
| Immunity, Cellular | 2 | 2012 | 1561 | 0.110 |
Why?
|
| Respiratory Insufficiency | 3 | 2021 | 1240 | 0.110 |
Why?
|
| Platelet Transfusion | 2 | 2000 | 301 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 1737 | 0.110 |
Why?
|
| Patient Isolation | 1 | 1994 | 101 | 0.110 |
Why?
|
| Drug Administration Schedule | 7 | 2014 | 4860 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2015 | 549 | 0.110 |
Why?
|
| Stress, Psychological | 2 | 2019 | 4530 | 0.110 |
Why?
|
| Cyclosporine | 4 | 2016 | 777 | 0.100 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 39348 | 0.100 |
Why?
|
| Pulmonary Edema | 3 | 2014 | 408 | 0.100 |
Why?
|
| Radiotherapy | 2 | 1998 | 1502 | 0.100 |
Why?
|
| Animals, Laboratory | 1 | 2012 | 46 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2021 | 1206 | 0.100 |
Why?
|
| Integrin alpha4 | 1 | 2012 | 88 | 0.100 |
Why?
|
| Integrin beta Chains | 1 | 2012 | 115 | 0.100 |
Why?
|
| Somatosensory Disorders | 1 | 2012 | 49 | 0.100 |
Why?
|
| Neoplasms | 13 | 2020 | 22371 | 0.100 |
Why?
|
| Species Specificity | 2 | 2015 | 2415 | 0.100 |
Why?
|
| Endometrium | 1 | 2015 | 406 | 0.100 |
Why?
|
| Specimen Handling | 2 | 1994 | 708 | 0.100 |
Why?
|
| Carmustine | 1 | 2012 | 137 | 0.100 |
Why?
|
| Respirovirus Infections | 1 | 2011 | 51 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2014 | 614 | 0.100 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 661 | 0.100 |
Why?
|
| Blood Banks | 1 | 2012 | 108 | 0.100 |
Why?
|
| Leukocytosis | 2 | 2009 | 251 | 0.090 |
Why?
|
| Time Factors | 13 | 2015 | 40218 | 0.090 |
Why?
|
| Antigens, CD34 | 3 | 2020 | 657 | 0.090 |
Why?
|
| B-Lymphocytes | 5 | 2015 | 4793 | 0.090 |
Why?
|
| Neutropenia | 2 | 2003 | 892 | 0.090 |
Why?
|
| Erythropoietin | 1 | 2015 | 718 | 0.090 |
Why?
|
| Progesterone | 1 | 2015 | 752 | 0.090 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2015 | 383 | 0.090 |
Why?
|
| Multiple Organ Failure | 3 | 2010 | 388 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2017 | 3114 | 0.090 |
Why?
|
| Recombinant Proteins | 8 | 2014 | 6514 | 0.090 |
Why?
|
| Health Resources | 1 | 2016 | 950 | 0.090 |
Why?
|
| Immunocompromised Host | 2 | 2012 | 863 | 0.090 |
Why?
|
| Infusions, Intravenous | 6 | 2014 | 2230 | 0.090 |
Why?
|
| Immunization, Passive | 1 | 1992 | 619 | 0.080 |
Why?
|
| Stem Cells | 2 | 2018 | 3537 | 0.080 |
Why?
|
| Bacterial Infections | 3 | 1998 | 1397 | 0.080 |
Why?
|
| Stomatitis | 1 | 1992 | 271 | 0.080 |
Why?
|
| Misonidazole | 1 | 1989 | 33 | 0.080 |
Why?
|
| Child, Preschool | 17 | 2019 | 42669 | 0.080 |
Why?
|
| Drug Evaluation | 7 | 2000 | 642 | 0.080 |
Why?
|
| Methotrexate | 4 | 2015 | 1721 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2016 | 5703 | 0.080 |
Why?
|
| Agranulocytosis | 1 | 1989 | 98 | 0.080 |
Why?
|
| Serotonin Antagonists | 2 | 2000 | 147 | 0.080 |
Why?
|
| Hematopoiesis | 5 | 2005 | 2059 | 0.080 |
Why?
|
| Amphotericin B | 1 | 1989 | 143 | 0.080 |
Why?
|
| Risk Factors | 8 | 2024 | 74944 | 0.080 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2017 | 4640 | 0.080 |
Why?
|
| Escherichia coli Infections | 1 | 2012 | 524 | 0.080 |
Why?
|
| Thioguanine | 1 | 1988 | 45 | 0.080 |
Why?
|
| Edema | 1 | 2012 | 765 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 3 | 2010 | 837 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2017 | 2258 | 0.070 |
Why?
|
| Estrogens | 1 | 2015 | 1536 | 0.070 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2009 | 289 | 0.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2014 | 616 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 11928 | 0.070 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2007 | 27 | 0.070 |
Why?
|
| Mitoxantrone | 1 | 1987 | 148 | 0.070 |
Why?
|
| Sirolimus | 2 | 2015 | 1540 | 0.070 |
Why?
|
| Ovarian Neoplasms | 4 | 2001 | 4916 | 0.070 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 1991 | 388 | 0.070 |
Why?
|
| Filgrastim | 1 | 2007 | 131 | 0.070 |
Why?
|
| Fibrinolytic Agents | 2 | 2010 | 2080 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2012 | 10760 | 0.070 |
Why?
|
| Cell Separation | 4 | 2016 | 1728 | 0.070 |
Why?
|
| Viremia | 1 | 2010 | 726 | 0.070 |
Why?
|
| Batroxobin | 1 | 1986 | 4 | 0.070 |
Why?
|
| Kidney | 3 | 2019 | 7064 | 0.070 |
Why?
|
| Chronic Disease | 6 | 2020 | 9384 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2009 | 1815 | 0.070 |
Why?
|
| Cytokines | 5 | 2015 | 7453 | 0.060 |
Why?
|
| Postoperative Complications | 5 | 2019 | 15832 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2012 | 1441 | 0.060 |
Why?
|
| Erythrocyte Transfusion | 1 | 1990 | 575 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 3187 | 0.060 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1986 | 187 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2010 | 753 | 0.060 |
Why?
|
| Killer Cells, Natural | 2 | 2005 | 2211 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2011 | 2521 | 0.060 |
Why?
|
| Morbidity | 1 | 2010 | 1755 | 0.060 |
Why?
|
| Leukemia, Myeloid | 3 | 2006 | 693 | 0.060 |
Why?
|
| Immunoglobulin G | 3 | 1992 | 4568 | 0.060 |
Why?
|
| Infection Control | 1 | 1992 | 985 | 0.060 |
Why?
|
| Leukocyte Count | 3 | 2015 | 1609 | 0.060 |
Why?
|
| Integrins | 1 | 2009 | 842 | 0.060 |
Why?
|
| Disease Management | 1 | 2015 | 2536 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 1994 | 2430 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 7454 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 3740 | 0.060 |
Why?
|
| Butanols | 1 | 2004 | 19 | 0.060 |
Why?
|
| Child | 19 | 2019 | 80917 | 0.060 |
Why?
|
| Defoliants, Chemical | 1 | 1984 | 9 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2015 | 4176 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 4282 | 0.060 |
Why?
|
| Clostridium | 1 | 2004 | 100 | 0.060 |
Why?
|
| Osteolysis | 1 | 1985 | 274 | 0.060 |
Why?
|
| Protozoan Infections | 1 | 2003 | 38 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 1994 | 2176 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2005 | 518 | 0.050 |
Why?
|
| Herbicides | 1 | 1984 | 104 | 0.050 |
Why?
|
| Prognosis | 5 | 2015 | 30010 | 0.050 |
Why?
|
| Peptide Hydrolases | 1 | 1986 | 610 | 0.050 |
Why?
|
| Blood | 1 | 1985 | 599 | 0.050 |
Why?
|
| Heat-Shock Response | 1 | 2004 | 179 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2014 | 2747 | 0.050 |
Why?
|
| Genes, bcl-2 | 1 | 2023 | 119 | 0.050 |
Why?
|
| Amyloidosis | 1 | 2010 | 878 | 0.050 |
Why?
|
| Major Histocompatibility Complex | 2 | 2017 | 877 | 0.050 |
Why?
|
| Cytarabine | 3 | 2014 | 695 | 0.050 |
Why?
|
| Adenocarcinoma | 3 | 1999 | 6395 | 0.050 |
Why?
|
| Hypercalcemia | 1 | 1985 | 424 | 0.050 |
Why?
|
| Hospitals, University | 2 | 2016 | 570 | 0.050 |
Why?
|
| Immunophenotyping | 3 | 2011 | 1864 | 0.050 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2005 | 454 | 0.050 |
Why?
|
| Transplantation, Heterologous | 3 | 1999 | 2393 | 0.050 |
Why?
|
| Family | 2 | 2007 | 3209 | 0.050 |
Why?
|
| Heart Transplantation | 2 | 2010 | 3301 | 0.050 |
Why?
|
| Lymphopoiesis | 1 | 2002 | 133 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2015 | 18349 | 0.050 |
Why?
|
| Thiotepa | 2 | 2014 | 66 | 0.050 |
Why?
|
| Bone Resorption | 1 | 1985 | 728 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2005 | 1156 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 2005 | 2000 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 10399 | 0.050 |
Why?
|
| Liver | 2 | 2015 | 7577 | 0.050 |
Why?
|
| Aspergillosis | 1 | 2003 | 242 | 0.050 |
Why?
|
| Biopsy | 5 | 2015 | 6793 | 0.050 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2003 | 238 | 0.050 |
Why?
|
| Graft vs Host Reaction | 1 | 2001 | 99 | 0.050 |
Why?
|
| Transplantation, Isogeneic | 1 | 2001 | 249 | 0.040 |
Why?
|
| Ovary | 1 | 2005 | 965 | 0.040 |
Why?
|
| Clinical Trials as Topic | 3 | 2002 | 8054 | 0.040 |
Why?
|
| Primates | 1 | 2023 | 520 | 0.040 |
Why?
|
| Oocytes | 1 | 2005 | 1172 | 0.040 |
Why?
|
| Minisatellite Repeats | 1 | 2001 | 162 | 0.040 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2000 | 58 | 0.040 |
Why?
|
| Anemia, Hemolytic | 1 | 1981 | 164 | 0.040 |
Why?
|
| Lymphocyte Activation | 3 | 2014 | 5505 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 2862 | 0.040 |
Why?
|
| Mice | 9 | 2012 | 82029 | 0.040 |
Why?
|
| Cyclosporins | 2 | 1991 | 216 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 1989 | 1183 | 0.040 |
Why?
|
| Pneumonia | 1 | 2012 | 2163 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 1437 | 0.040 |
Why?
|
| Atovaquone | 1 | 1999 | 56 | 0.040 |
Why?
|
| Hospitalization | 5 | 2017 | 10840 | 0.040 |
Why?
|
| Infant | 9 | 2016 | 36535 | 0.040 |
Why?
|
| DNA Primers | 3 | 2012 | 2828 | 0.040 |
Why?
|
| Solubility | 2 | 2012 | 1083 | 0.040 |
Why?
|
| Cell Lineage | 2 | 2006 | 2575 | 0.040 |
Why?
|
| Neutrophils | 3 | 2016 | 3786 | 0.040 |
Why?
|
| Survivors | 2 | 2024 | 2381 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 696 | 0.040 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2001 | 260 | 0.040 |
Why?
|
| Cryopreservation | 2 | 2016 | 733 | 0.040 |
Why?
|
| Plasminogen Activators | 2 | 1997 | 199 | 0.040 |
Why?
|
| Lymphoma, Follicular | 1 | 2003 | 460 | 0.040 |
Why?
|
| Prospective Studies | 8 | 2018 | 54926 | 0.040 |
Why?
|
| Tacrolimus | 2 | 2015 | 750 | 0.040 |
Why?
|
| Thyroglobulin | 1 | 2019 | 111 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2018 | 5315 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 446 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2011 | 3073 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 1942 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2003 | 1353 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 5367 | 0.040 |
Why?
|
| Antibodies, Heterophile | 1 | 1999 | 128 | 0.040 |
Why?
|
| Bone Marrow Purging | 1 | 1998 | 108 | 0.040 |
Why?
|
| Neoplasm Metastasis | 3 | 2000 | 4912 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2012 | 1361 | 0.040 |
Why?
|
| Ciprofloxacin | 1 | 2020 | 313 | 0.040 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 1 | 1998 | 45 | 0.040 |
Why?
|
| Penicillins | 1 | 1981 | 406 | 0.040 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2004 | 1137 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 2000 | 475 | 0.040 |
Why?
|
| Ursodeoxycholic Acid | 1 | 1997 | 81 | 0.040 |
Why?
|
| Cell Count | 2 | 2009 | 1832 | 0.040 |
Why?
|
| Leukapheresis | 2 | 2012 | 150 | 0.040 |
Why?
|
| Hormones | 1 | 2021 | 866 | 0.040 |
Why?
|
| Receptors, Serotonin | 1 | 1998 | 211 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2018 | 4415 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 1989 | 2541 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2003 | 724 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 4058 | 0.030 |
Why?
|
| Spleen | 1 | 2023 | 2295 | 0.030 |
Why?
|
| Vincristine | 2 | 2010 | 1040 | 0.030 |
Why?
|
| Pulmonary Fibrosis | 4 | 1991 | 506 | 0.030 |
Why?
|
| Registries | 3 | 2016 | 8375 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 1793 | 0.030 |
Why?
|
| Liver Failure | 1 | 1998 | 252 | 0.030 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 2663 | 0.030 |
Why?
|
| Fatigue | 2 | 2016 | 1557 | 0.030 |
Why?
|
| Nitriles | 1 | 2021 | 980 | 0.030 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 2337 | 0.030 |
Why?
|
| Skin Diseases | 3 | 2012 | 1085 | 0.030 |
Why?
|
| Pedigree | 2 | 2015 | 4539 | 0.030 |
Why?
|
| Inpatients | 2 | 2017 | 2566 | 0.030 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 1996 | 97 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 2002 | 945 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 640 | 0.030 |
Why?
|
| Killer Cells, Lymphokine-Activated | 2 | 1992 | 42 | 0.030 |
Why?
|
| Longitudinal Studies | 3 | 2015 | 14783 | 0.030 |
Why?
|
| Bangladesh | 1 | 2016 | 742 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 899 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 1994 | 363 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 526 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2010 | 41754 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2010 | 9419 | 0.030 |
Why?
|
| Benzylamines | 1 | 2015 | 251 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 2015 | 245 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1999 | 1207 | 0.030 |
Why?
|
| Biological Availability | 1 | 1994 | 389 | 0.030 |
Why?
|
| Ileal Diseases | 1 | 1994 | 70 | 0.030 |
Why?
|
| Infant, Newborn | 4 | 2016 | 26422 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 427 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 2 | 1997 | 1165 | 0.030 |
Why?
|
| Half-Life | 1 | 1994 | 651 | 0.030 |
Why?
|
| Administration, Oral | 2 | 1994 | 4030 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2015 | 22291 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2000 | 12465 | 0.030 |
Why?
|
| Safety | 1 | 1998 | 1159 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 5863 | 0.030 |
Why?
|
| Embryo Implantation | 1 | 2015 | 272 | 0.030 |
Why?
|
| Massachusetts | 2 | 2017 | 8890 | 0.030 |
Why?
|
| Papio | 3 | 1999 | 671 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 2 | 2006 | 351 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1673 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 1998 | 2916 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 3814 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2000 | 1179 | 0.030 |
Why?
|
| Immunotoxins | 1 | 2012 | 175 | 0.020 |
Why?
|
| District of Columbia | 1 | 1992 | 159 | 0.020 |
Why?
|
| Doxorubicin | 2 | 2010 | 2234 | 0.020 |
Why?
|
| Antigens, CD | 3 | 2007 | 4035 | 0.020 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2011 | 25 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 840 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2015 | 1183 | 0.020 |
Why?
|
| Touch | 1 | 1994 | 316 | 0.020 |
Why?
|
| Neuroblastoma | 2 | 1992 | 1266 | 0.020 |
Why?
|
| SRS-A | 1 | 1991 | 132 | 0.020 |
Why?
|
| Thromboxane B2 | 1 | 1991 | 143 | 0.020 |
Why?
|
| Tissue Preservation | 1 | 1991 | 173 | 0.020 |
Why?
|
| Lymphatic Irradiation | 1 | 2011 | 115 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2001 | 20227 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2012 | 252 | 0.020 |
Why?
|
| Aftercare | 1 | 2017 | 916 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2021 | 2028 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2004 | 3840 | 0.020 |
Why?
|
| Pregnancy | 3 | 2015 | 30256 | 0.020 |
Why?
|
| Mediastinum | 1 | 2012 | 272 | 0.020 |
Why?
|
| Inbreeding | 1 | 2009 | 48 | 0.020 |
Why?
|
| Interferon-gamma | 2 | 2010 | 3160 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1992 | 1377 | 0.020 |
Why?
|
| Cell Survival | 1 | 2000 | 5777 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2012 | 794 | 0.020 |
Why?
|
| Bence Jones Protein | 1 | 2009 | 19 | 0.020 |
Why?
|
| Erythrocytes | 2 | 2016 | 2418 | 0.020 |
Why?
|
| Telomere | 1 | 2015 | 944 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 3 | 2020 | 7477 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 1998 | 6316 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 2009 | 154 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 657 | 0.020 |
Why?
|
| Immunity, Innate | 2 | 2018 | 3080 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2015 | 3447 | 0.020 |
Why?
|
| Body Weight | 1 | 2020 | 4627 | 0.020 |
Why?
|
| Complement C4b | 1 | 2009 | 124 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 3048 | 0.020 |
Why?
|
| Attitude to Health | 1 | 1998 | 2025 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 414 | 0.020 |
Why?
|
| Pseudotumor Cerebri | 1 | 1990 | 107 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 27360 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2009 | 412 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 1990 | 331 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 6082 | 0.020 |
Why?
|
| Secondary Prevention | 2 | 2007 | 1474 | 0.020 |
Why?
|
| Prednisone | 2 | 2010 | 1567 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2011 | 420 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2011 | 1169 | 0.020 |
Why?
|
| Lung Diseases, Interstitial | 2 | 1994 | 940 | 0.020 |
Why?
|
| Mass Screening | 1 | 2024 | 5458 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1998 | 1944 | 0.020 |
Why?
|
| Immunization | 1 | 2012 | 1219 | 0.020 |
Why?
|
| International Cooperation | 1 | 2014 | 1436 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 610 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2018 | 2197 | 0.020 |
Why?
|
| Alanine | 1 | 2010 | 614 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1990 | 348 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2012 | 1617 | 0.020 |
Why?
|
| Azacitidine | 1 | 2009 | 336 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 1990 | 419 | 0.020 |
Why?
|
| Macrocyclic Compounds | 1 | 2007 | 67 | 0.020 |
Why?
|
| Uric Acid | 1 | 2014 | 805 | 0.020 |
Why?
|
| Age Factors | 2 | 2015 | 18412 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 399 | 0.020 |
Why?
|
| Receptors, Complement 3b | 1 | 2007 | 136 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 1989 | 479 | 0.020 |
Why?
|
| Culture Media | 2 | 2004 | 898 | 0.020 |
Why?
|
| Cardiotonic Agents | 1 | 2010 | 542 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 165 | 0.020 |
Why?
|
| Erythroblasts | 1 | 2007 | 142 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 6029 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 1991 | 772 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 1662 | 0.020 |
Why?
|
| Esophageal Stenosis | 1 | 1988 | 196 | 0.020 |
Why?
|
| Gangliosides | 1 | 1987 | 132 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 2627 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2000 | 2819 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1994 | 1126 | 0.020 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2006 | 49 | 0.020 |
Why?
|
| Patient Admission | 1 | 1994 | 1365 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 11095 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2011 | 1695 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 277 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2014 | 9669 | 0.020 |
Why?
|
| Heart Failure | 1 | 2010 | 11879 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 1998 | 2056 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2009 | 855 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1990 | 569 | 0.020 |
Why?
|
| Nephritis, Hereditary | 1 | 2006 | 78 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 646 | 0.020 |
Why?
|
| Melanoma | 3 | 1992 | 5706 | 0.020 |
Why?
|
| Sterilization, Reproductive | 1 | 2005 | 24 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2009 | 599 | 0.020 |
Why?
|
| Mycophenolic Acid | 1 | 2007 | 348 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 1918 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1990 | 1826 | 0.020 |
Why?
|
| Cough | 1 | 2009 | 598 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 1382 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2016 | 2523 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 3488 | 0.020 |
Why?
|
| Plasmacytoma | 1 | 2006 | 170 | 0.020 |
Why?
|
| Daunorubicin | 1 | 1985 | 157 | 0.020 |
Why?
|
| Genotype | 1 | 2000 | 13045 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1994 | 2885 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1984 | 174 | 0.010 |
Why?
|
| Myeloid Cells | 1 | 2010 | 839 | 0.010 |
Why?
|
| Oogenesis | 1 | 2005 | 125 | 0.010 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 9538 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2000 | 5341 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 12543 | 0.010 |
Why?
|
| Hepatitis | 1 | 1986 | 227 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2007 | 921 | 0.010 |
Why?
|
| Base Sequence | 2 | 2009 | 12421 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1990 | 716 | 0.010 |
Why?
|
| Developing Countries | 1 | 2016 | 2910 | 0.010 |
Why?
|
| Host vs Graft Reaction | 1 | 2003 | 13 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 794 | 0.010 |
Why?
|
| Immune System | 1 | 2009 | 799 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 1990 | 13586 | 0.010 |
Why?
|
| Comorbidity | 1 | 2018 | 10590 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2010 | 2661 | 0.010 |
Why?
|
| Rabbits | 1 | 2010 | 4772 | 0.010 |
Why?
|
| Monocytes | 2 | 2009 | 2605 | 0.010 |
Why?
|
| Spores, Bacterial | 1 | 2004 | 114 | 0.010 |
Why?
|
| Platelet Count | 1 | 2006 | 787 | 0.010 |
Why?
|
| Receptors, KIR | 1 | 2003 | 114 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 1994 | 2784 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 1061 | 0.010 |
Why?
|
| Intestines | 1 | 2012 | 1909 | 0.010 |
Why?
|
| Vietnam | 1 | 1984 | 415 | 0.010 |
Why?
|
| Cell Movement | 1 | 2015 | 5210 | 0.010 |
Why?
|
| Preleukemia | 1 | 1982 | 34 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2003 | 199 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1985 | 547 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 2003 | 132 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1987 | 1652 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 13014 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 1754 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 2633 | 0.010 |
Why?
|
| Viral Load | 1 | 2011 | 3396 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2020 | 13053 | 0.010 |
Why?
|
| Phenotype | 1 | 2000 | 16726 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2002 | 313 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2002 | 318 | 0.010 |
Why?
|
| Bilirubin | 1 | 2002 | 438 | 0.010 |
Why?
|
| Ascites | 1 | 2002 | 338 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2009 | 4146 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1995 | 11244 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2001 | 330 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 1625 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2001 | 766 | 0.010 |
Why?
|
| Oxygen | 1 | 2011 | 4270 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 59629 | 0.010 |
Why?
|
| Stem Cell Factor | 1 | 2000 | 194 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 1996 | 0.010 |
Why?
|
| Kinetics | 2 | 2002 | 6329 | 0.010 |
Why?
|
| Spinal Neoplasms | 1 | 1985 | 715 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2015 | 10474 | 0.010 |
Why?
|
| Blood Cells | 1 | 2001 | 309 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6526 | 0.010 |
Why?
|
| Cell Line | 2 | 2009 | 15597 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1986 | 1198 | 0.010 |
Why?
|
| Heparin | 1 | 1986 | 1636 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2000 | 425 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1990 | 4352 | 0.010 |
Why?
|
| Microspheres | 1 | 2002 | 788 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2009 | 2479 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2003 | 1418 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2001 | 528 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2009 | 5151 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2003 | 952 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2010 | 5622 | 0.010 |
Why?
|
| Ureter | 1 | 1999 | 364 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3800 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 2810 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1999 | 910 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1992 | 15948 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2001 | 1733 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2015 | 24315 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 3445 | 0.010 |
Why?
|
| Models, Psychological | 1 | 1998 | 825 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1999 | 1096 | 0.010 |
Why?
|
| Plasma Substitutes | 1 | 1993 | 57 | 0.010 |
Why?
|
| Personal Satisfaction | 1 | 1998 | 643 | 0.010 |
Why?
|
| Lymphokines | 1 | 1996 | 924 | 0.010 |
Why?
|
| United States | 1 | 2021 | 73039 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 1996 | 344 | 0.010 |
Why?
|
| Family Health | 1 | 1998 | 1255 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 18065 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 12800 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 9561 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1999 | 1162 | 0.010 |
Why?
|
| Electrolytes | 1 | 1993 | 279 | 0.010 |
Why?
|
| Epitopes | 1 | 1999 | 2528 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1998 | 2923 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1981 | 1398 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1993 | 386 | 0.010 |
Why?
|
| Self Concept | 1 | 1998 | 1043 | 0.010 |
Why?
|
| Ileum | 1 | 1994 | 558 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1990 | 5432 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 15454 | 0.010 |
Why?
|
| Leukotriene E4 | 1 | 1991 | 75 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2009 | 5176 | 0.010 |
Why?
|
| Muscle Cramp | 1 | 1990 | 33 | 0.010 |
Why?
|
| Sex Factors | 1 | 1984 | 10632 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1999 | 3556 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 7608 | 0.010 |
Why?
|
| ROC Curve | 1 | 1998 | 3628 | 0.010 |
Why?
|
| Veterans | 1 | 1984 | 2669 | 0.010 |
Why?
|
| Hybridomas | 1 | 1991 | 444 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 1989 | 216 | 0.000 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1989 | 510 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1998 | 6340 | 0.000 |
Why?
|
| Leukocytes | 1 | 1996 | 2035 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 9615 | 0.000 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1990 | 425 | 0.000 |
Why?
|
| Liver Diseases | 1 | 1996 | 1305 | 0.000 |
Why?
|
| Esophagitis | 1 | 1988 | 164 | 0.000 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1986 | 63 | 0.000 |
Why?
|
| Cystadenocarcinoma | 1 | 1986 | 54 | 0.000 |
Why?
|
| Gene Expression | 1 | 1999 | 7598 | 0.000 |
Why?
|
| Disease Progression | 1 | 2003 | 13671 | 0.000 |
Why?
|
| Myocardium | 1 | 1999 | 4788 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 14729 | 0.000 |
Why?
|
| DNA | 1 | 1999 | 7214 | 0.000 |
Why?
|
| Leukemia, Lymphoid | 1 | 1985 | 311 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1998 | 12077 | 0.000 |
Why?
|
| Antigens | 1 | 1990 | 1442 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2004 | 12168 | 0.000 |
Why?
|
| Cisplatin | 1 | 1990 | 1660 | 0.000 |
Why?
|
| Pain | 1 | 1998 | 5100 | 0.000 |
Why?
|
| Autopsy | 1 | 1986 | 1011 | 0.000 |
Why?
|
| Hysterectomy | 1 | 1986 | 863 | 0.000 |
Why?
|
| Central Nervous System Diseases | 1 | 1985 | 520 | 0.000 |
Why?
|
| Diarrhea | 1 | 1985 | 1320 | 0.000 |
Why?
|
| Life Expectancy | 1 | 1985 | 1248 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1991 | 19015 | 0.000 |
Why?
|